Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3698 PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma

Introduction: Management of metastatic insulinoma (MI) presents dual management challenges of hypoglycaemia (hypo) and progressive oncologic disease. Case reports describe remarkable responses to PRRT but limited follow-up (FU).

Conference:

Presenting Author: Pattison D

Authors: Pattison D, Kong G, Hofman M, Akhurst T, Ravi Kumar A,

Keywords: Insulinoma, PRRT, hypoglycaemia, [177Lu]Lu-DOTATATE,

#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)

Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kong G

Authors: Kong G, Grozinsky-Glasberg S, Akhurst T, Hofman M, Meirovitz A,

Keywords: PRRT, Lu-177, metastatic, Rectal, Neuroendocrine neoplasm,

#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: kong G

Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,

Keywords: PRRT,

#1391 Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)

Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,

Keywords: PRRT, Y-90,